Related Experiment Video
Updated: May 28, 2026
Reconstruct Human Retinoblastoma In Vitro
Published on: October 11, 2022
Retinoblastoma and Its Tumor Microenvironment
Ashwinaa M Vaithianathan1, George Zanazzi2,3,4
1Rhodes College, Memphis, TN 38112, USA.
Abstract:
Retinoblastoma is the most common intraocular malignancy of childhood and is most often driven by loss of the RB1 tumor suppressor gene. While current treatments achieve high survival rates, they are frequently associated with significant morbidity, highlighting the need for more precise, biology-driven therapeutic methods. Increasing evidence suggests that retinoblastoma progression is not dictated by neoplastic cells alone, but rather by complex interactions within the tumor microenvironment, including stromal and immune components. In this review, we examine the cellular and molecular landscape of retinoblastoma with a particular focus on the immune microenvironment, including the spatial distribution and functional roles of innate and adaptive immune cells, as well as immune checkpoint proteins such as PD-1, PD-L1, and CTLA-4. We discuss how tumor- and treatment-induced immune suppression shapes disease progression and therapeutic response, and how chemotherapy alters immune infiltration and checkpoint expression. Finally, we explore emerging immunotherapeutic and cell-based approaches, emphasizing the potential for combination therapies that integrate immune modulation to improve outcomes and reduce long-term toxicity in retinoblastoma.
Insights
Retinoblastoma, a childhood eye cancer, involves complex tumor microenvironment interactions. Understanding the immune microenvironment offers new avenues for targeted therapies to improve outcomes and reduce side effects.
Area of Science:
- Pediatric Oncology
- Immunology
- Ophthalmology
Background:
- Retinoblastoma is the most common childhood intraocular cancer, often linked to RB1 gene loss.
- Current treatments yield high survival but cause significant morbidity, necessitating advanced therapeutic strategies.
- Tumor progression is influenced by interactions within the tumor microenvironment, including immune and stromal cells.
Purpose of the Study:
- To review the cellular and molecular characteristics of the retinoblastoma immune microenvironment.
- To explore the roles of innate and adaptive immune cells and immune checkpoint proteins (PD-1, PD-L1, CTLA-4).
- To discuss immune suppression, chemotherapy effects, and emerging immunotherapeutic strategies.
Main Methods:
- Literature review focusing on retinoblastoma immunology and tumor microenvironment.
- Analysis of immune cell distribution, function, and immune checkpoint expression.
- Examination of therapeutic strategies, including immunotherapy and cell-based approaches.
Main Results:
- The immune microenvironment significantly impacts retinoblastoma progression and treatment response.
- Immune suppression, influenced by tumor and treatment, plays a critical role.
- Chemotherapy affects immune cell infiltration and checkpoint molecule expression.
Conclusions:
- Targeting the immune microenvironment holds promise for novel retinoblastoma treatments.
- Combination therapies integrating immune modulation may enhance efficacy and reduce toxicity.
- Further research into immune-based strategies is crucial for improving pediatric eye cancer care.
Related Concept Videos
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:17The Tumor Microenvironment
02:17The Tumor Microenvironment